Schubert & Co’s NovoCure NVCR Stock Holding History

Schubert & Co’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	1252
2021 Q4	$0	Buy	+1	New	+$100	﹤0.01%	1198

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schubert & Co's NVCR Position: Q1 2022 in Review

Schubert & Co sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 1 share.

Schubert & Co first reported a position in NVCR in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 308 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Schubert & Co reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Schubert & Co sold 1 NovoCure share in Q1 2022.
Schubert & Co first reported a position in NovoCure in Q4 2021 and held it in 1 quarter.
Schubert & Co's NovoCure position peaked at $0 in Q4 2021.
308 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Schubert & Co's 13F filing for Q1 2022, filed 16 May 2022.